About this trial
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver. This blockage can cause problems like an enlarged spleen, bleeding from swollen veins in the digestive system, and low blood cell counts. Many of these patients may have hidden blood disorders that increase the risk of clotting, such as myeloproliferative neoplasms (MPNs), antiphospholipid syndrome (APS), or paroxysmal nocturnal hemoglobinuria (PNH). This study will collect and analyze blood test results-such as complete blood count (CBC), liver function tests (LFTs), and clotting tests-from patients with EHPVO. The aim is to find patterns that may suggest an underlying blood disorder, even if the patient doesn't show obvious symptoms.By understanding these patterns early, doctors may be able to diagnose and treat the root causes of clotting in these patients more accurately, helping prevent complications and improve outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years or older . Diagnosis of extra hepatic portal vein obstruction based on imaging ( Doppler, CT , MRI ) preserved liver function . Available complete medical records including CBC , LFTs and coagulation profile .
Disqualifiers
Patients with cirrhosis or intrahepatic portal hypertension • Incomplete or missing medical records • Patients with known hematologic malignancies or undergoing chemotherapy
Trial population
Adult patients diagnosed with EHPVO between 2020 and 2024 in a tertiary care hospital in Cairo. Data will be collected retrospectively from medical records
Trial design
Case-only
Retrospective
Treatments tested in this trial
No intervention (Observational Study)
Other interventionThis is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only
Treatment groups
Trial outcomes
Primary outcomes
Frequency of hematological disorders in EHPVO patients
The proportion of EHPVO Patients showing hematological disorders including cytopenias ( thrombocytopenia , anemia , leukopenia ) and coagulation disturbances based on retrospective laboratory data
Frequency of hematological disorders in EHPVO patients
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Rahab Nady
Lead sponsor
Assiut University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: